Shortly after canning its lead and acquiring the NK cell company Cytosen, Kiadis flips part of the tech to Sanofi.
A recent technology deal with Notch points to a problem that all allogeneic cell therapy players might sooner or later have to tackle.
Kadmon awaits key graft-versus-host disease data, and Surface Oncology's change of tack comes under the spotlight.
EU rejection of Kiadis's stem cell transplant adjunct means that two of three players in this space have been knocked back.
The ripples of Molmed’s pivotal study failure could stretch beyond the company’s Zalmoxis product.
Perhaps sensing trouble ahead Kiadis diversifies beyond ATIR101 by buying Cytosen, but it is a scientific appointment that will cause real excitement.